Trials / Completed
CompletedNCT00307593
RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides
Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides With Positive ANCA After Relapse or Resistant Immunosuppressant Therapies
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Assistance Publique - Hôpitaux de Paris · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare a 2 immunosuppressant regimen for the treatment of relapsing or refractory necrotizing antineutrophil cytoplasmic antibody (ANCA) associated vasculitides.
Detailed description
The aim of this study is to compare the efficacy of rituximab versus infliximab in relapsing or refractory forms of ANCA+ vasculitides (Microscopic Polyangiitis, Wegener's granulomatosis and Churg-Strauss syndrome).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Infliximab | Infliximab |
| DRUG | Rituximab | Rituximab |
Timeline
- Start date
- 2004-05-01
- Completion
- 2007-06-01
- First posted
- 2006-03-28
- Last updated
- 2007-11-19
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT00307593. Inclusion in this directory is not an endorsement.